We studied 13 @entity1 aged 29-62 years for response to weekly administration of @entity1311 for metastatic @entity0 . @entity1311 was administered by 1-hour intravenous infusion at a dose of 60-80 mg/m2 once a week. Administration was continued for 3 weeks with a 1-week rest for at least 3 cycles. This was first-line treatment in 1 @entity1 , second-line treatment in 7, and third-line treatment in 5. The overall response rate was 68% among 13 partial responders and there were no complete responders. By recurrence site, the response rate was 71% in the liver, 75% in the lung, 18% in bone, and 67% at local sites. @entity158 was ameliorated in 4 of 8 @entity1 and local recurrence of @entity5 decreased in 6 of 8 cases. Tumor markers decreased in 6 of 12 cases. Time to progression reached beyond 6 months in 6 of 13 cases, and was limited to within only 3 months in 6 cases. In terms of survival, 4 of 13 @entity1 who were treated by @entity1311 as a 3rd line treatment for liver or lung metastasis died within 3 months after administration. Weekly administration of @entity1311 appears to be effective against metastatic @entity0 . However, the selection of cases based on the timing of administration is considered to be important to prolong the @entity1054 and improve survival.

[Clinical study of weekly XXXX administration for metastatic @entity0 based on @entity1054 ( @entity1054 ) and survival].

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['time to progression']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
